+

WO2003099013A1 - Composition a base de glucosamine et medicament anti-inflammatoire a base de paracetamol/non steroide - Google Patents

Composition a base de glucosamine et medicament anti-inflammatoire a base de paracetamol/non steroide Download PDF

Info

Publication number
WO2003099013A1
WO2003099013A1 PCT/US2000/027931 US0027931W WO03099013A1 WO 2003099013 A1 WO2003099013 A1 WO 2003099013A1 US 0027931 W US0027931 W US 0027931W WO 03099013 A1 WO03099013 A1 WO 03099013A1
Authority
WO
WIPO (PCT)
Prior art keywords
glucosamine
acetaminophen
parts
weight
nsaid
Prior art date
Application number
PCT/US2000/027931
Other languages
English (en)
Inventor
Lindsay Duncan
Original Assignee
Omni Nutraceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omni Nutraceuticals, Inc. filed Critical Omni Nutraceuticals, Inc.
Priority to AU2000280045A priority Critical patent/AU2000280045A1/en
Publication of WO2003099013A1 publication Critical patent/WO2003099013A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine

Definitions

  • Field of the Invention is directed to a composition, a dietary regimen and a method. More specifically, this invention is directed to a dietary regimen and formulation having improved gastrointestinal absorption and systemic utilization of nutritional materials for abatement of the symptoms associated with arthritis.
  • the dietary regimen of this invention is also effective in the reversal of the degeneration caused by arthritis by the repair and/or replacement of mammalian joint connective tissue that has deteriorated and/or been damaged incident to disease and/or injury.
  • Description of the Prior Art - The increase in life expectancy of Americans from 1930 to 1980 can, in part, be attributed to the improvement in nutrition in the United States during that period.
  • Limiting menu choices also causes a depletion of essential amino acids, such as tryptophan which is important precursor of neurotransmitters and that may play a role in the prevention of memory function deterioration with aging.
  • the availability of essential nutrients is further compromised by poor gastrointestinal absorption.
  • the traditional way to offset insufficient nutrients in the diet, insufficient gastrointestinal absorption and or insufficient metabolic utilization of essential nutrients, is to administer relatively large doses of vitamins, mineral and other dietary/nutritional supplements.
  • Vitamin, mineral and other dietary/nutritional supplements Unfortunately, simply increasing the quantity of such essential nutrients, via ingestion of such supplements, does not necessarily increase their systemic availability, because of self-limiting factors associated with digestion and/or the body's internal mechanism regulating their availability. This is particularly apparent in the case of the treatment and/or abatement of the degenerative processes associated with arthritis.
  • glycosaminoglycans e.g. chondroitin sulfate
  • aspirin has been disclosed in combination with glycosaminoglycans (e.g. chondroitin sulfate) as a therapy to abate the symptoms associated with arthritis
  • glycosaminoglycans e.g. chondroitin sulfate
  • Kerzberg, E. M., et al Combination of Glycosaminoglycans & Acetylsalicylic Acid In Knee Osteoarthritis, Scand. J. Rheumatorlogy, 16:377-380, (1987).
  • the Kerzberg article concludes that, based upon the then available knowledge as to the physiological effects of the individual components, the aspirin and the chondroitin were likely synergists.
  • the Henderson '845 patent describes and claims a dietary regimen and composition for the abatement of the symptoms of arthritis comprising glucosamine salts, chondroitin salts and manganese.
  • the Burger '919 patent describes and claims a dietary regimen and composition for the abatement of the symptoms of arthritis comprising one or more glucosamine salts and one or more omega-3 fatty acids (EDA, DHA and their mixture).
  • Each of the Henderson and Burger patents are exclusive of co-administration of their respective compositions and an NSAID; and, must rely upon one or more additional ingredients in their formulation for immediate abatement of the inflammation associated with arthritis.
  • Neither Henderson nor Burger patents contemplate the addition of any agent to enhance absorption and/or to increase the systemic availability of the glucosamine; and, it is assumed that the prescribed dosage levels attain adequate systemic levels of the essential ingredients to achieve the intended results.
  • the administration of their patented compositions is based upon a daily regimen, and contemplates a daily dosage sufficient to reverse the degeneration of the effected connective tissue.
  • the effectiveness of the dietary regimen is based, in part, on the ability of such nutrients to alter the metabolic pathways associated with cartilage formation so as to increase the utilization of essential nutrients in the synthesis of healthy cartilage.
  • the amount of supplements required to achieve this desired result is generally directly related to the weight of the individual and indirectly related to the absorption and availability of the supplement in sufficient amounts to drive the reaction equilibrium in the desired direction to accomplish the desired result.
  • the biochemical pathway for the synthesis of collagen from simple sugars is reversible unless reaction conditions, favoring its formation, drive the reaction equilibrium in the direction of such synthesis.
  • reaction kinetics are based upon the relative amounts of glucosamine that is formed, and the further transformation thereof into proteoglycans (the precursor of cartilage).
  • proteoglycans the precursor of cartilage.
  • the transformation thereof into proteoglycans does not occur.
  • glucosamine containing dietary supplements in order for glucosamine containing dietary supplements to be effective, such supplements must contain relative large amounts of glucosamine and/or be taken in accordance with a dietary regimen that insures adequate amounts be ingested to provide the required systemic level to accomplish the desired cartilage synthesis.
  • Additional objects of this invention include the formulation of the dietary supplement of this invention in a convenient dosage form.
  • a daily regimen of supplements including a formulation comprising (a) natural ingredients and derivatives of natural ingredients generally characterized as chondroprotective nutrients/supplements, (b) acetaminophen or a non-steroidal anti-inflammatory (NSAID) at a level sufficient to enhance the bioavailabihty of said chondroprotective nutrients/supplements, and, optionally, (c) an additional bioavailablity enhancer for the natural ingredients and derivatives of natural ingredients.
  • NSAID non-steroidal anti-inflammatory
  • the unique formulation of this invention has improved gastrointestinal absorption and systemic utilization of nutritional materials for abatement of the symptoms associated with arthritis. Moreover, it is believed that each of the acetaminophen/NSAID enhances the systemic bioavailability of the chondroprotective agents, and, thus, their more effective individual roles and synergy relative to each other.
  • the preferred dietary regimen of this invention involves the administration, on a daily basis, of effective amounts, (consistent with the attainment of one or more of the above stated Objects of the Invention), of the following supplements
  • glucosamine e.g. glucosamine sulfate, glucosamine hydrochloride, N-acetyl-glucosamine
  • glucosamine salts e.g. glucosamine sulfate, glucosamine hydrochloride, N-acetyl-glucosamine
  • NSAID non-steroidal anti-inflammatory
  • the amount of acetaminophen or NSAED compound(s) in this formulation or administered in the daily regimen can range from about 25% to 35% below an amount traditional regarded as therapeutic up to an including the 100% to 150% of the amount traditionally regarded within the therapeutic range (e.g. 325 to 500 mgs aspirin per therapeutic dosage; 200 to 300 mgs of ibuprofen per therapeutic dosage, etc.).
  • the chondroprotective agent in the formulation and daily regimen can also be administered in an amount below that which is required of more traditional preparations because of the enhancement in the systemic bioavailability of such nutrients as a result of their co-administration with the acetaminophen or NSAID.
  • the body's demands for chondroprotective agents and acetaminophen or NSAID is more than adequately met to abate the symptoms of arthritis, notwithstanding that the amounts thereof which is administered has been reduced from that normally prescribed.
  • the beneficial effects of the formulation are less dosage dependent, in that the systemic level of the chondroprotective agents are enhanced as a result of the presence of each of the acetaminophen or NSAID; and, can be further enhanced, as desired, by the addition of an alkaloid pipeline extract to the formulation.
  • the glucosamine and chondroitin component(s) of the composition stimulate the biosynthesis of the glycosaminoglycans and the hyaluronic acid backbone needed for the formation of proteoglycans found in the structural matrix of the joints.
  • the addition of the acetaminophen or NSAID compound also participate in the process of symptomatic relief from the pain and stiffness associated with arthritis, however, their role in this regard is perceived to be subordinate to the chondroprotective agents, and primarily in the enhancement of the absorption and systemic utilization of the chondroprotective agents.
  • the reaction kinetics which favor the synthesis and regeneration of joint cartilage is biased in favor of cartilage synthesis/regeneration, thereby affording the individual afflicted with arthritis, long term relief.
  • the addition of the alkaloid extract of pipeline to the formulation is believed to enhance the systemic utilization of the acetaminophen or NSAID, even at what is generally regarded as sub-therapeutic levels, to further reduce inflammation of the effected joint, and thereby provide more immediate symptomatic relief from the pain and swelling of the arthritic joints.
  • the NSAID compound (also “cyclooxygenase inhibitor”) is derived from a natural or synthetic form of a compound selected from the group consisting of methyl salicylic acid, salicylsalicylic acid, salicylic acid, trilisate, sadalcid, and salts thereof (hereinafter also collectively “aspirin”).
  • aspirin methyl salicylic acid, salicylsalicylic acid, salicylic acid, trilisate, sadalcid, and salts thereof.
  • the form of the aspirin and the amount thereof is well tolerated at the contemplated daily dosage; and, its ingestion/digestion otherwise unremarkable at the contemplated daily dosage do to the form thereof, and/or the presence of additional ingredients (e.g. natural or synthetic buffers).
  • the recommended daily consumption of a combination of dietary supplements (based upon a body weight in the range of from about 50 to about 200 lbs.) is as follows:
  • the glucosamine and chondroitin are present in a sufficient daily dosage to arrest the deterioration of the connective tissues in the joint and, over time, promote the regeneration of healthy tissue.
  • the other components of the composition acetaminophen or NSAID
  • the dosage form of the composition can include any conveniently dispensable preparation, (e.g. tablets, softgel capsules, liquid elixir, etc.).
  • the dosage form preferable contains all of the essential ingredients in a single, easily ingestible form, that can be taken at different times throughout the day (e.g. to correspond with meals). Once symptomatic relief has been attained, it is preferable that the daily dosage, be biased in favor or morning and mid-day administration of the composition, with little if any additional ingestion, taking place in the evening (to optimize digestion and uptake)
  • Novel Composition It has been discovered that a combination therapy of glucosamine (and its corresponding salts), chondroitin (and its corresponding salts), and acetaminophen or NSAID provides effective symptomatic relief from the associated pain and discomfort associated with arthritis; and, can arrest, and in time reverse, the progression of the disease.
  • the acetaminophen or NSAID functions in this formulation both to enhance absorption of the chondroprotective agents and as a source of immediate relief of the pain associated with arthritis.
  • an alkaloid extract of pipeline is also present to further enhance the absorption of all of the essential ingredient of the formulation, including specifically, the chondroprotective agents.
  • the formulation of this invention can also contain the mineral manganese, and preferably an organic salt of manganese, such as manganese ascorbate, to promote the conversion of nutrients to collagen.
  • the aspirin can be administered at 25 to 50% below an amount considered to be within the therapeutic range; or, alternatively, when administered at therapeutic levels (e.g. about 7.5 to 15 mgs/kg body weight) is enteric-coated or buffered.
  • therapeutic levels e.g. about 7.5 to 15 mgs/kg body weight
  • the herb, Musa sapientum, (or the active ingredient thereof, flavonoid leucocyanidin) can also be included in such preferred composition to reduce the potential irritating side effects of aspirin and as protective agent for the GI tract and to inhibit aspirin-induced erosions of the stomach lining in sensitive individuals.
  • glucosamine provides the primary substrate for both collagen and proteoglycan synthesis.
  • Glucosamine is available from a number of natural sources and/or can be synthetically derived.
  • Glucosamine is the preferred substrate for proteoglycan synthesis, including chondroitin sulfates and hyaluronic acid.
  • the glucosamine component of the novel combination is, preferably, in a salt form so as to facilitate its delivery and uptake by the digestive system.
  • the preferred salts of glucosamine include N-acetyl- glucosamine, glucosamine hydrochloride and glucosamine sulfate and mixtures thereof.
  • glucosamine localizes to cartilage and joint tissues, where it remains for extended periods, until neeeded in the synthesis/regeneration of connective tissues.
  • the retalive systemic level of glucosamine is critical to drive the reaction kinetics to collagen formation. Accordingly, it is preferable to provide sufficient glucosamine to increase the systemic level thereof to effectively drive the reaction equilibrium in the direction of collagen formation.
  • glucosamine is effective to accomplish the purposes of this invention.
  • Chondroitin Component - Chondroitin is a polysulfonated glycosaminoglycan composed of repeating structural units of glucose which provides the framework or template for the remodeling of connective tissue such as cartilage; and, further provides the cartilage with its flexibility, resiliency and resistance to compression (shock absorbing properties). More specifically, there are multiple synthetic pathways for the formatoin of cartilage (depending upon the substrate/starting materials); and, in each instance glucosamine is an intermediate in the formatoin of the desired product.
  • the Henderson '845 patent is exemplary of this process. In brief, one pathway involves the conversion of simple sugars to a more complex sugar, mucopolysaccharides (e.g.
  • glycosaminoglycans glycosaminoglycans
  • glucosamine N-acetyly-glucosamine
  • This maturation step involves an accretive process wherein glycosaminoglycan simply increases in mass and thereby forms collagen. This maturation is facilitated by the chondroitin which provides a substrate for the synthesis of the proteoglycans, such glycosaminoglycans.
  • acetaminophen or non-steroidal anti- inflamatory drugs (NSAID) suitable for use in the formulation of this invention include many of the well-known over the counter and prescription products prescribed for relief of pain and discomfort associated with muscle and joint discomfort.
  • the preferred acetaminophen suitable for use in this invention is a Tylenol-like preparation.
  • the preferred NSAID suitable for use in this invention includes aspirin, naproxen, piroxicam, indomethacin, sulindac, meclofenamate, difusinal, tolmetin, ibuprofen, fenoprofen, etodolac, ketorolac, dicofenac, ketoprofen, nabumetone, and acetaminophen, their corresponding salts, their corresponding isomers and mixtures thereof.
  • the accepted and prescibed unit dosage for the acetaminophen or NSAIDs contemplated for use in this invention can range from about 325 mgs for the lesser effective drugs (e.g.
  • the formulation of this invention optionally contains an additional nutrient, absortion enhancer effective amount of an alkaloid extract of pipeline. This compound is available commercially from Sabinsa Corporation (Piscataway, NJ) under the brand name, Bioperine ® .
  • This commercial product which is an acceptable source of the pipeline extract, is dereived from black pepper and reportedly contains at least 95% alkaloid pipeline. This product is also reportedly described in US 5,536,506, which is herein incorporated by reference in its entirety). This compound is effective to enhance the bioavailability of the active ingredients of the formulation when present at a concentration ranging from about 0.1 to about 1.0 weight percent.
  • Optional Ingredients are as follows: shark cartilage; cayenne; turmeric (curcuma longa); boswellia serrata; devil's claw; cat's claw; sea cucumber; yucca; alfalfa; chlorella; quercetin; calcium, magnesium; type II collagen; vitamin C; vitamin E; CoQ 10; bromelain; zinc; manganese; MSM (methyl-sulfonyl-methane); and CMO (cetylmyristoleate).
  • the composition is administered for a time sufficient to reduce or control the symptoms of arthritis and other joint discomforts.
  • One or two doses of the composition may be sufficient, or the composition may be administered on an ongoing basis for several days or weeks, even months in duration.
  • Variables related to the amount of the composition to be administered include the severity of symptoms, the species of animals to be treated, and the body weight of the animal.
  • the composition is administered at a dosage of between 1.5 to about 275 mgs of the combined glucosamine, chondroitin, and aspirin, (other natural ingredients) per kilogram of the body weight per day irrespective of species.
  • the amount of alkaloid extract of pipeline per dose, when present, is preferably in the range of from about 0.004 to 0.08 mg/kg of body weight.
  • the formulation of this invention may be administered, if desired, in divided doses, such as BID, TID, or QID. The following recommended treatment is both safe and effective for relief from the symptomatic effects of arthritis.
  • glucosamine and chondroitin require that both of them be taken a minimum of twice; and, for better results, three times a day.
  • the pain associated with arthritis will begin to subside immediately, and, thereafter such treatment provides essentially continuous relief so long as the regimen is followed. In most individuals such treatment will slow down or even reverses the progression of the disease.
  • the regimen is discontinued, the debilitating pain may return within a brief period (4-7 days).
  • the therapeutic effects of the formulation provides pain relief for an even longer period (up to 14 days) after treatment has been discontinued. In any event, upon resumption of the regimen, the pain once again is abated, and no side effects are experienced even after several months of continued use.
  • a formulation of this invention is prepared in tabletted form by mixing unit doses of the following components: 325 mg enteric coated or buffered aspirin, 500 mg glucosamine sulfate, and 400 mg chondroitin sulfate.
  • This unit dosage is efficacious in a dietary regimen wherein the individual weighs from about 100 to about 125 lbs. and takes at least one dose of this formulation in the morning and a second dose in the evening.
  • the dietary regimen contemplates that, at a minimum, one additional dose be taken in the morning and in the evening.
  • the unit dosage specified in the regimen is 2x to 3x the mimmum dosage.
  • EXAMPLE 2 The procedures of Example 1 are repeated, except for the substitution of a unit dose of 200 mgs of the NSAID, ibuprofen, for a unit dose of the aspirin component of the formulation.
  • EXAMPLE 3 The procedures of Example 1 are repeated, except for the substitution of the a unit dose of 220 mgs of the NSAID, naproxen sodium, for a unit dose of the aspirin component of the formulation.
  • EXAMPLE 4 The procedures of Example 1 are repeated, except for the reduction in the unit dose of the aspirin component of the formulation from 325 mgs to 243 mgs/unit dose.
  • Example 6 The procedures of Example 1 are repeated, except for the substitution of a natural source of an NSAID, White Willow Bark (15% salicylic acid), for the aspirin component of the formulation. The unit dose of White Willow Bark is adjusted to deliver the therapeutic equivalent of aspirin.
  • Example 1 The procedures of Example 1 are repeated, except for the substitution of acetaminophen for the aspirin component of the formulation.
  • the unit dose of acetaminophen is adjusted to deliver the therapeutic equivalent of aspirin.
  • Example 7 The procedures of Example 1-5 are repeated, wherein each of the formulations of Examples 1-6 are modified to include 150 mgs manganese ascorbate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un complément alimentaire contenant des ingrédients naturels, notamment une glucosamine, et les dérivés de tels ingrédients naturels combiné à un médicament anti-inflammatoire à base de paracétamol ou non stéroïde (SNAID). Cette combinaison est spécialement indiquée pour le soulagement immédiat ou la suppression de symptômes associés à l'arthrite, à des troubles semblables et à des lésions semblables qui se manifestent par le gonflement et l'inflammation des articulations et des tissus conjonctifs au sein des articulations. La présence d'un médicament anti-inflammatoire à base de paracétamol ou non stéroïde (NSAID) dans la composition semble augmenter les niveaux systémiques de la glucosamine dans le sang et prouve, de ce fait, que la glucosamine convient à la formation de cartilage. La composition peur renfermer des ingrédients éventuels, tels que la vitamine C, la vitamine E, du magnésium et d'autres substances existant à l'état naturel.
PCT/US2000/027931 2000-01-24 2000-10-10 Composition a base de glucosamine et medicament anti-inflammatoire a base de paracetamol/non steroide WO2003099013A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2000280045A AU2000280045A1 (en) 2000-01-24 2000-10-10 Acetaminophen/non-steroidal anti-inflamatory drug-glucosamine composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48977900A 2000-01-24 2000-01-24
US09/489,779 2000-01-24

Publications (1)

Publication Number Publication Date
WO2003099013A1 true WO2003099013A1 (fr) 2003-12-04

Family

ID=29584706

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/027931 WO2003099013A1 (fr) 2000-01-24 2000-10-10 Composition a base de glucosamine et medicament anti-inflammatoire a base de paracetamol/non steroide

Country Status (2)

Country Link
AU (1) AU2000280045A1 (fr)
WO (1) WO2003099013A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005116086A3 (fr) * 2004-04-07 2006-08-24 Univ Georgia Res Ct Inc Glucosamine et promédicaments mutuels anti-inflammatoires, compositions et procédés à base de glucosamine
WO2009065604A2 (fr) * 2007-11-23 2009-05-28 Bayer Consumer Care Ag Composition pharmaceutique
US8034796B2 (en) 2004-04-07 2011-10-11 The University Of Georgia Research Foundation, Inc. Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
EP2460514A1 (fr) 2010-12-03 2012-06-06 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions de gel pharmaceutique topique de flurbiprofène, glucosamine et chondroïtine
WO2012095726A1 (fr) * 2011-01-10 2012-07-19 Abdi Ibrahim Ilac Sanayyi Ve Ticaret Anonim Sirketi Association pharmaceutique contenant des sels de glucosamine et du paracétamol pour le traitement de l'arthrose
EP1883416A4 (fr) * 2005-05-24 2013-06-12 Wellgen Inc Compositions et procedes pour la prevention et le traitement de conditions associees a l'inflammation
US8703741B2 (en) * 2004-12-28 2014-04-22 Mestex Ag Method of treating articular pain using a vanilloid receptor agonist together with a glycosaminoglycan or proteoglycan

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587363A (en) * 1993-03-31 1996-12-24 Nutramax Laboratories, Inc. Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue
US5840715A (en) * 1995-12-11 1998-11-24 Inholtra Investment Holdings & Trading, N.V. Dietary regimen of nutritional supplements for relief of symptoms of arthritis
US5843919A (en) * 1996-11-25 1998-12-01 Burger; John A. Composition and method for the treatment of arthritis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587363A (en) * 1993-03-31 1996-12-24 Nutramax Laboratories, Inc. Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue
US5840715A (en) * 1995-12-11 1998-11-24 Inholtra Investment Holdings & Trading, N.V. Dietary regimen of nutritional supplements for relief of symptoms of arthritis
US5843919A (en) * 1996-11-25 1998-12-01 Burger; John A. Composition and method for the treatment of arthritis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BARKAY ET AL.: "The prostaglandin inhibitor effect of antiinflammatory drugs in the therapy of male infertility", FERTILITY & STERILITY, vol. 42, no. 3, September 1984 (1984-09-01), pages 406 - 411, XP002935066 *
VAN DER KRAAK ET AL.: "Arachidonic acid stimulates steroidogenesis in goldfish preovulatory ovarian follicles", GEN. AND COMP. ENDOCRINOLOGY, vol. 77, 1990, pages 221 - 228, XP002935067 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005116086A3 (fr) * 2004-04-07 2006-08-24 Univ Georgia Res Ct Inc Glucosamine et promédicaments mutuels anti-inflammatoires, compositions et procédés à base de glucosamine
US8034796B2 (en) 2004-04-07 2011-10-11 The University Of Georgia Research Foundation, Inc. Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
US8361990B2 (en) 2004-04-07 2013-01-29 University Of Georgia Research Foundation, Inc. Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
US8703741B2 (en) * 2004-12-28 2014-04-22 Mestex Ag Method of treating articular pain using a vanilloid receptor agonist together with a glycosaminoglycan or proteoglycan
EP1883416A4 (fr) * 2005-05-24 2013-06-12 Wellgen Inc Compositions et procedes pour la prevention et le traitement de conditions associees a l'inflammation
WO2009065604A2 (fr) * 2007-11-23 2009-05-28 Bayer Consumer Care Ag Composition pharmaceutique
WO2009065604A3 (fr) * 2007-11-23 2009-10-08 Bayer Consumer Care Ag Composition pharmaceutique
EA019542B1 (ru) * 2007-11-23 2014-04-30 Байер Конзумер Кэр Аг Фармацевтическая композиция
EP2460514A1 (fr) 2010-12-03 2012-06-06 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions de gel pharmaceutique topique de flurbiprofène, glucosamine et chondroïtine
TR201010074A1 (tr) * 2010-12-03 2012-06-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Flurbiprofen, glukosamin ve kondroitin topikal farmasötik jel bileşimleri.
WO2012095726A1 (fr) * 2011-01-10 2012-07-19 Abdi Ibrahim Ilac Sanayyi Ve Ticaret Anonim Sirketi Association pharmaceutique contenant des sels de glucosamine et du paracétamol pour le traitement de l'arthrose

Also Published As

Publication number Publication date
AU2000280045A1 (en) 2003-12-12

Similar Documents

Publication Publication Date Title
US5053429A (en) Treating inflammatory pain with methionine
JP2667351B2 (ja) 食餌脂質消化吸収阻害剤および飲食品
US6809115B2 (en) Methods and compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols
US5840715A (en) Dietary regimen of nutritional supplements for relief of symptoms of arthritis
US6136795A (en) Dietary regimen of nutritional supplements for relief of symptoms of arthritis
AU2023200826B2 (en) Administration of berberine metabolites
US20120004157A1 (en) Hydroxyproline compositions and uses thereof
JP4738464B2 (ja) アディポネクチン分泌促進用飲食品
EP0855908B1 (fr) Regime alimentaire a base de complements nutritionnels permettant de soulager les symptomes de l'arthrite
CA2376008A1 (fr) Combinaison de glucosamine avec des extraits d'herbes de tripterygium, ligustrum et erycibe
WO2003099013A1 (fr) Composition a base de glucosamine et medicament anti-inflammatoire a base de paracetamol/non steroide
CA2514687A1 (fr) Composition de pointe a base de vitamine c possedant des capacites ameliorees de biotransformation et utilisation de proteines et de l-carnitine comme additifs nutritionnels ou comme substances de meme nature
JP2003504408A (ja) 炎症及び／又は退行性疾患に対処する組成物
US20160114002A1 (en) Compositions comprising plant proteins and methods for prevention of metabolic and cardiovascular pathologies in patient with cardiometabolic risk, including hyperglycemia
JP5156330B2 (ja) 脂肪組織重量減少剤
JP2001524080A (ja) 関節炎の治療用加水分解コラーゲンタンパク質およびグルコサミンを含む組成物
GB2286528A (en) Dietary supplement
WO2014015462A1 (fr) Aubépine et phytostérols et leurs effets sur les troubles métaboliques
JP4914594B2 (ja) 関節痛改善用食品組成物
JP2001048802A (ja) 糖尿病に有効な健康補助食品およびその使用方法、並びに糖尿病に有効な食品配合剤
JP2004041006A (ja) 液状栄養組成物
WO2002028400A1 (fr) Formulation therapeutique contenant de la glucosamine, du dimethylsulfone et eventuellement de l'acide ascorbique et du manganese
AU5778801A (en) Improvements in effervescent tablet manufacture
Holt Bone and Joint Health: Part 2—Dietary Supplements
WO2024030207A1 (fr) Compositions d'agmatine pour le traitement de l'arthrose

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN IL JP KR MX NZ SG ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载